Sunday, February 15, 2026 2/15/2026

Parasite-specific proteasome inhibitors to combat multi-drug resistant malaria

Award Number: R33AI127581
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/09/2016
PERIOD OF PERFORMANCE END DATE: 02/28/2023

Group Awards By:

View Award Description

Parasite-specific proteasome inhibitors to combat multi-drug resistant malaria - Project Summary Multidrug-resistant forms of Plasmodium falciparum contribute directly to the massive global burden of malaria, which, as of 2015, impacts nearly 200 million people and result in over 400,000 deaths per year. P. falciparum resistance to the former first-line drugs chloroquine and pyrimethamine-sulfadoxine has now exacerbated the emergence and spread of resistance to the current first-line drug artemisinin (ART) and some partner drugs used in first line artemisinin (ART)-based combination therapies (ACTs). To achieve the stated goal of malaria elimination, new therapeutic strategies are essential to eliminate multi-drug resistant parasites. Recent studies of ART-resistant parasite strains suggest that they can resist drug-mediated killing by up-regulation of the unfolded protein response (UPR), a process that depends on activation of the multi-catalytic proteasome complex. Consequently, proteasome inhibitors have been shown to be highly synergistic with ART derivatives. Unlike ART, these inhibitors are also active liver, gametocyte and oocyst stages. Therefore, compounds that selectively target the Plasmodium proteasome have the potential to be curative while also blocking transmission from human to insect vector and reducing the emergence of drug resistance. We hypothesize that ART, as well as other classes of current anti-malarial drugs and preclinical candidates, induce stress pathways in P. falciparum that depend on proteasomal activity to achieve resistance. We also hypothesize that proteasome inhibitors have the potential to be broadly used to suppress the onset of multidrug resistance in native parasite populations. This proposal is built around strong preliminary results using substrate screening assays and our recently solved cryo-electron microscopy structure of the P. falciparum 20S proteasome to design selective inhibitors of the parasite proteasome with nanomolar potency that effectively clear rodent malaria infections in vivo. We find that proteasome inhibitors show a high degree of synergism when combined with ART and are potent against ART-resistant field isolates. Our preliminary results therefore establish the paradigm that the proteasome is a viable anti-malarial drug target. We propose developing improved parasite-specific proteasome inhibitors that have enhanced potency, selectivity and bioavailability while simultaneously defining the mechanism and conditions by which inhibitors can optimally synergize with anti-malarial agents to prevent the spread of resistance.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Allergy and Infectious Diseases Research	000	5	1/16/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	LELAND STANFORD JUNIOR UNIVERSITY, THE	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Allergy and Infectious Diseases Research	000	5	11/18/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	LELAND STANFORD JUNIOR UNIVERSITY, THE	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Allergy and Infectious Diseases Research	000	5	9/14/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $454,467 )
2021	2021	LELAND STANFORD JUNIOR UNIVERSITY, THE	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Allergy and Infectious Diseases Research	000	5	11/9/2020	NON-COMPETING CONTINUATION	$454,467
														Subtotal = $454,467

Issue Date FY: 2020 ( Subtotal = $462,817 )
2020	2020	LELAND STANFORD JUNIOR UNIVERSITY, THE	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Allergy and Infectious Diseases Research	000	4	11/26/2019	NON-COMPETING CONTINUATION	$462,817
														Subtotal = $462,817

Issue Date FY: 2019 ( Subtotal = $519,218 )
2019	2019	LELAND STANFORD JUNIOR UNIVERSITY, THE	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Allergy and Infectious Diseases Research	001	3	5/7/2019	EXTENSION WITH OR WITHOUT FUNDS	$34,175
2019	2019	LELAND STANFORD JUNIOR UNIVERSITY, THE	450 SERRA MALL	STANFORD	CA	94305	SANTA CLARA	USA	Allergy and Infectious Diseases Research	000	3	12/18/2018	EXTENSION WITH OR WITHOUT FUNDS	$485,043
														Subtotal = $519,218

Grand Total All Awards = $1,436,502

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Parasite-specific proteasome inhibitors to combat multi-drug resistant malaria

Award Number: R33AI127581

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/09/2016

PERIOD OF PERFORMANCE END DATE: 02/28/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer